Network meta-analysis compares efficacy and safety of anti-CGRP treatments in chronic migraine patients.
To compare the efficacy and safety of different doses of anti-CGRP monoclonal antibodies (Eptinezumab and Erenumab) in chronic migraine patients with medication overuse headache using a network meta-analysis.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: